Clinical trial
Rosiglitazone in Treating Patients With Liposarcoma
NCT00004180 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00004180 |
|---|---|
| Title | Rosiglitazone in Treating Patients With Liposarcoma |
| Official title | Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With Liposarcoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | rosiglitazone maleate |
| Enrollment | 32 |
| Start date | Oct 1, 1999 |
| Primary completion | Mar 1, 2006 |
| Completion | May 1, 2015 |
| First posted | May 9, 2003 |
| Last update posted | Jun 26, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: